Nanobiotix is at the forefront of developing innovative cancer therapies through its lead product, NBTXR3, which is a potential first-in-class radioenhancer. This technology utilizes hafnium oxide nanoparticles, designed to enhance the effectiveness of radiotherapy by significantly increasing the energy deposited within tumor cells while minimizing damage to surrounding healthy tissues. NBTXR3 is administered via a one-time injection directly into the tumor before standard radiotherapy, allowing for a localized increase in radiation absorption. Clinical data indicate that this approach can lead to substantial tumor cell death and may also prime the immune system to better recognize and attack cancer cells, potentially improving overall treatment outcomes.

The company’s focus on physics-based nanotherapeutics aims to address the limitations of traditional cancer treatments, particularly in solid tumors. NBTXR3 is currently being evaluated in various clinical trials across multiple cancer types, including head and neck cancer, soft tissue sarcoma, and others. The technology's mechanism of action is based on physical principles rather than biological or chemical interactions, suggesting broad applicability across different solid tumors and treatment regimens. As such, Nanobiotix is positioning NBTXR3 to potentially become a new standard of care in radiation oncology, offering hope for improved efficacy and safety in cancer treatment.

France

Nanobiotix has been pioneering nanomedicine for more than 17 years to bring a different approach to medicine.
Our therapeutic technologies are not based on biology or chemistry – they are based on physical principles at nanoscale. This paradigm shift has allowed us to discover novel approaches to improving treatment outcomes.
Our company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. With this approach, our ambition is to benefit millions of patients who receive radiation therapy by improving the efficiency of radiation in tumor cells without increasing the dose received by surrounding healthy tissues. We believe that radiotherapy combined with NBTXR3 can become a new standard of care in the treatment of cancer.
By viewing the human body through the lens of physics a new realm of possibilities has emerged.

Cancer

Immune System Diseases

Liver Diseases

Lung Diseases

Urogenital Diseases

Nanobiotix 

Head and neck cancer

NBTXR3 is a first-in-class radioenhancer composed of sterile, functionalized, crystalline hafnium oxide nanoparticles. The product candidate is designed to increase the radiotherapy energy deposit inside tumor cells through the nanoparticles’ high atomic number core packaged in the space for interaction with ionizing radiation, and subsequently increase of tumor cell death when compared to radiotherapy alone—without adding toxicity to adjacent healthy tissues. NBTXR3 requires a single,
intratumoral administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide standards of radiation care. The primary physical mechanism of action of NBTXR3 activated by radiotherapy could be universal, making it potentially applicable across any solid tumor indication where radiotherapy is a part of standard of care including head and neck, lung, prostate, liver, colorectal, and esophageal cancers. The biological secondary mechanism of action of NBTXR3 activated by radiotherapy has been shown in preclinical studies to prime adaptive immune response, which would potentially bring a new dimension to cancer immunotherapies
<a href="https://www.nanobiotix.com/wp-content/uploads/2021/03/PR_AACR-RSM-2021-NBTXR3-Combo-Pre-clinical-Results_03022021.pdf">Source</a>

Nanobiotix

Company Details